TSE:4502Pharmaceuticals
Is TAK-881’s Reduced-Volume PID Infusion Data Altering The Investment Case For Takeda (TSE:4502)?
Earlier this month, Takeda Pharmaceutical reported that its pivotal Phase 2/3 trial of investigational PID therapy TAK-881 met its primary pharmacokinetic endpoint, showing comparable IgG exposure, efficacy and safety to HYQVIA, while potentially allowing patients to receive equivalent immunoglobulin doses in roughly half the infusion volume.
Because TAK-881 may offer shorter, lower-volume infusions with once-monthly flexibility, it could meaningfully change treatment convenience for Primary...